its starting to look that way. But yes, have a look at the...

its starting to look that way. But yes, have a look at the dot/plot(?) charts at the back of the ANP combo results announcement and you'll see the 'exon skip' works better with our cd49D drug. Our next announcement on that will hopefully explain what's going on... or we may never know. But I just can't see the logic in such a big company like Sarepta rolling the dice on everything they have by not partnering with us. Pfizer and others doing DMD gene therapy have all their other drugs to nurture, and wont be destroyed at all if Sarepta grab all the DMD sales. Sarepta has much more at risk. I see the MOD combo announcement coming up a window to negotiate with a big player. Could Sarepta use our combo patent to sell in the EU market to ambulant kids. In return they distribute us for the non ambulant population in the USA. They piggy back on us, us on them... for a price as we can go to both.